口服减重药获批之后:支付端才是放量的真正闸门

同花顺
5 hours ago

11月12日,国家药监局官网显示,礼来(LLY)申报的1类创新药(886015)奥氟格列隆钙片获批上市,商品名穆优达,适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。这是国内首个获批用于成人体重管理的口服GLP-1受体激动剂。消息落地后,减重药赛道再度成为市场讨论的焦点,产业链上固体制剂、原料药(884143)、渠道端的关注度同步升温。但把获批等同于放量...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10